Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Published:2023-05 Issue:5 Volume:24 Page:535-552
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hillmen Peter,Pitchford Alexandra,Bloor Adrian,Broom Angus,Young Moya,Kennedy Ben,Walewska Renata,Furtado Michelle,Preston Gavin,Neilson Jeffrey R,Pemberton Nicholas,Sidra Gamal,Morley Nicholas,Cwynarski Kate,Schuh Anna,Forconi Francesco,Elmusharaf Nagah,Paneesha Shankara,Fox Christopher P,Howard Dena R,Hockaday Anna,Brown Julia M,Cairns David A,Jackson Sharon,Greatorex Natasha,Webster Nichola,Shingles Jane,Dalal Surita,Patten Piers E M,Allsup David,Rawstron Andrew,Munir Talha

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial;Shanafelt;Blood,2022

2. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies;Burger;Leuk Lymphoma,2022

3. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma;Munir;Am J Hematol,2019

4. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL;Woyach;N Engl J Med,2018

5. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial;Moreno;Lancet Oncol,2019

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia;Expert Review of Anticancer Therapy;2024-09-02

2. Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors;Critical Reviews in Oncology/Hematology;2024-09

3. Should We Note Subset #2-Positive Patients as a Specific Group Within Mutated or Unmutated CLL?;Clinical Lymphoma Myeloma and Leukemia;2024-09

4. ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia;Annals of Oncology;2024-09

5. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice;Blood Neoplasia;2024-09